Recent advances in positron emission tomography imaging of brain

Drugs of the Future

Volumn 36, Issue 8, 2011, Pages 601-613

  Seneca, Nicholas ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ATOMOXETINE; BAPINEUZUMAB; BIOLOGICAL MARKER; CARBON 11; FLUORINE 18; GADOLINIUM; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NISOXETINE; NORADRENALIN TRANSPORTER; PBR 28; PLACEBO; RADIOLIGAND; REBOXETINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN DISEASE; BRAIN FUNCTION; BRAIN STEM; FOLLOW UP; HUMAN; MICROGLIA; MOLECULAR IMAGING; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCHIZOPHRENIA; THALAMUS;

EID: 80052895269     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.36.8.1633941     Document Type: Review

References (133)

1. Lee, C.M., Farde, L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006, 27(6): 310-6.
2. Wong, D.F., Tauscher, J., Grunder, G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009, 34(1): 187-203.
3. Ichise, M., Meyer, J.H., Yonekura, Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001, 42(5): 755-63.
4. Innis, R.B., Cunningham, V.J., Delforge, J. et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007, 27(9): 1533-9.
5. Volkow, N.D., Fowler, J.S., Wang, G., Ding, Y., Gatley, S.J. Mechanism of action of methylphenidate: Insights from PET imaging studies. J Atten Disord 2002, 6(Suppl. 1): S31-43.
6. Volkow, N.D., Wang, G.J., Fowler, J.S. et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998, 155(10): 1325-31.
7. Seibyl, J., Jennings, D., Tabamo, R., Marek, K. Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research. Q J Nucl Med Mol Imaging 2005, 49(2): 215-21.
8. Emond, P., Guilloteau, D., Chalon, S. PE2I: A radiopharmaceutical for in vivo exploration of the dopamine transporter. CNS Neurosci Ther 2008, 14(1): 47-64.
9. Laakso, A., Hietala, J. PET studies of brain monoamine transporters. Curr Pharm Des 2000, 6(16): 1611-23.
10. 11C]raclopride. Biol Psychiatry 2010, 68(10): 964-70.
11. 11C]DASB positron emission tomography. Psychopharmacology (Berl) 2007, 193(4): 539-45.
12. 11C]DASB positron emission tomography study. Am J Psychiatry 2004, 161(5): 826-35.
13. 2. Psychopharmacology (Berl) 2010, 210(3): 331-6.
14. 2. Psychopharmacology (Berl) 2006, 188(1): 119-27.
15. Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H.Y., Kalka, S., Dilley, G., Ordway, G.A. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997, 17(21): 8451-8.
16. Goddard, A.W., Ball, S.G., Martinez, J., Robinson, M.J., Yang, C.R., Russell, J.M., Shekhar, A. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety 2010, 27(4): 339-50.
17. Sofuoglu, M., Sewell, R. A. Norepinephrine and stimulant addiction. Addict Biol 2009, 14(2): 119-29.
18. Haenisch, B., Bonisch, H. Depression and antidepressants: Insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 2011, 129(3): 352-68.
19. Xu, F., Gainetdinov, R.R., Wetsel, W.C. et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 2000, 3(5): 465-71.
20. Haller, J., Bakos, N., Rodriguiz, R.M., Caron, M.G., Wetsel, W.C., Liposits, Z. Behavioral responses to social stress in noradrenaline transporter knockout mice: Effects on social behavior and depression. Brain Res Bull 2002, 58(3): 279-84.
21. Ding, Y.S., Lin, K.S., Logan, J. PET imaging of norepinephrine transporters. Curr Pharm Des 2006, 12(30): 3831-45.
22. 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET. Bioorg Med Chem 2007, 15(2): 616-25.
23. Stehouwer, J.S., Goodman, M.M. Fluorine-18 radiolabeled PET tracers for imaging monoamine transporters: Dopamine, serotonin, and norepinephrine. PET Clin 2009, 4(1): 101-28.
24. 2. Eur Neuropsychopharmacol 2005, 15(5): 517-20.
25. 3H]MeNER to norepinephrine transporters. Synapse 2005, 56(2): 100-4.
26. Logan, J., Ding, Y.S., Lin, K.S., Pareto, D., Fowler, J., Biegon, A. Modeling and analysis of PET studies with norepinephrine transporter ligands: The search for a reference region. Nucl Med Biol 2005, 32(5): 531-42.
27. 11C]MeNER. Nucl Med Biol 2003, 30(7): 707-14.
28. 11C]MeNER. J Cereb Blood Flow Metab 2005, 25: S599.
29. 11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter. Eur J Nucl Med Mol Imaging 2007, 34(5): 688-93.
30. 11C]O-methyl reboxetine and PET: Problems and progress. Nucl Med Biol 2007, 34(6): 667-79.
31. 11C]MeNER. Neuroimage 2004, 22(Suppl. 2): 30.
32. Hannestad, J., Gallezot, J.D., Planeta-Wilson, B. et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010, 68(9): 854-60.
33. 11C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. Neuroimage 2011, 56(1): 268-79.
34. 2. Eur J Nucl Med Mol Imaging 2009, 36(8): 1308-14.
35. 11C]O-methylreboxetine and HRRT. Synapse 2010, 64(1): 30-8.
36. Schou, M., Halldin, C., Sovago, J. et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 2004, 53(2): 57-67.
37. 11C]MeNER. Eur J Nucl Med Mol Imaging 2009, 36(11): 1885-91.
38. 2. J Nucl Med 2008, 49(8): 1270-6.
39. Takano, A., Nag, S., Gulyas, B., Halldin, C., Farde, L. NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in nonhuman primates in vivo. Psychopharmacology (Berl) 2011, 216(2): 279-86.
40. 2. Neuroimage 2008, 42(2): 474-82.
41. Schou, M., Pike, V.W., Halldin, C. Development of radioligands for imaging of brain norepinephrine transporters in vivo with positron emission tomography. Curr Top Med Chem 2007, 7(18): 1806-16.
42. 11C]nisoxetine, a norepinephrine uptake inhibitor. Int J Rad Appl Instrum B 1989, 16(8): 771-4.
43. Nguyen, V.L., Pichika, R., Bhakta, P.H., Kant, R., Mukherjee, J. (R)-NMethyl- 3-(3′-[F]fluoropropyl)phenoxy)-3-phenylpropanamine (F-MFP3) as a potential PET imaging agent for norepinephrine transporter. J Labelled Compd Radiopharm 2010, 53(4): 172-7.
44. Musachio, J.L., Hong, J., Ichise, M. et al. Development of new brain imaging agents based upon nocaine-modafinil hybrid monoamine transporter inhibitors. Bioorg Med Chem Lett 2006, 16(12): 3101-4.
45. 11C]talsupram: Candidate PET ligands for the norepinephrine transporter. Nucl Med Biol 2004, 31(6): 705-18.
46. 11C]talsupram. Mol Imaging Biol 2006, 8(1): 1-8.
47. 3H] nisoxetine binding to uptake sites for norepinephrine in the locus coeruleus of humans. Brain Res 1992, 583(1-2): 312-5.
48. 3H]Nisoxetine: A radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 1992, 260(1): 427-36.
49. 3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 1993, 157(2): 203-6.
50. Farde, L., Hall, H. Positron emission tomography - Examination of chemical transmission in the living human brain. Development of radioligands. Arzneimittelforschung 1992, 42(2A): 260-4.
51. 2 receptor in nonhuman primates. Synapse 1992, 10(3): 177-84.
52. Laruelle, M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 2000, 20(3): 423-51.
53. Moghaddam, B., Berridge, C.W., Goldman-Rakic, P.S., Bunney, B.S., Roth, R.H. In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse 1993, 13(3): 215-22.
54. Saunders, R.C., Kolachana, B.S., Weinberger, D.R. Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: An in vivo microdialysis study. Exp Brain Res 1994, 98(1): 44-52.
55. Laruelle, M., Iyerm R.N., al-Tikritim M.S. et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997, 25(1): 1-14.
56. Breier, A., Su, T.P., Saunders, R. et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997, 94(6): 2569-74.
57. Tokunaga, M., Seneca, N., Shin, R.M. et al. Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. J Neurosci 2009, 29(6): 1887-96.
58. Creese, I., Sibley, D.R., Leff, S.E. Agonist interactions with dopamine receptors: Focus on radioligand-binding studies. Fed Proc 1984, 43(13): 2779-84.
59. George, S.R., Watanabe, M., Di Paolo, T., Falardeau, P., Labrie, F., Seeman, P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985, 117(2): 690-7.
60. 2 receptor binding sites for agonists. A tetrahedral model. Mol Pharmacol 1985, 28(5): 391-9.
61. Sibley, D.R., Mahan, L.C., Creese, I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Mol Pharmacol 1983, 23(2): 295-302.
62. 2 receptors. Nucl Med Biol 2000, 27(6): 533-9.
63. 11C]MNPA in cynomolgus monkey. Nucl Med Biol 2005, 32(4): 353-60.
64. 2 high-affinity state with positron emission tomography. J Med Chem 2005, 48(12): 4153-60.
65. 2 receptors in vivo using positron emission tomography. J Neurochem 2006, 97(4): 1089-103.
66. 11C]raclopride in baboons. J Pharmacol Exp Ther 2005, 315(1): 80-90.
67. 11C]raclopride. Synapse 2006, 59(5): 260-9.
68. 11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 2010, 333(2): 533-9.
69. 11C]-(+)- PHNO positron emission tomography study. Neuropsychopharmacology 2008, 33(2): 279-89.
70. Laruelle, M., Abi-Dargham, A., van Dyck, C.H. et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996, 93(17): 9235-40.
71. Perry, V.H., Nicoll, J.A., Holmes, C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6(4): 193-201.
72. Graeber, M.B. Changing face of microglia. Science 2010, 330(6005): 783-8.
73. 11C]PK11195 positron emission tomography study. Biol Psychiatry 2008, 64(9): 820-2.
74. Papadopoulos, V., Baraldi, M., Guilarte, T.R. et al. Translocator protein (18 kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006, 27(8): 402-9.
75. Cosenza-Nashat, M., Zhao, M.L., Suh, H.S., Morgan, J., Natividad, R., Morgello, S., Lee, S.C. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009, 35(3): 306-28.
76. Versijpt, J., Debruyne, J.C., Van Laere, K.J. et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: A correlative study. Mult Scler 2005, 11(2): 127-34.
77. Banati, R.B., Newcombe, J., Gunn, R.N. et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000, 123(Pt. 11): 2321-37.
78. 18F]pyrazolo[1,5- a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. J Med Chem 2008, 51(13): 3700-12.
79. 11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage 2008, 39(3): 1289-98.
80. 11C]DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009, 50(8): 1276-82.
81. 11C]DAA1106. J Cereb Blood Flow Metab 2007, 27(1): 173-84.
82. Kuhlmann, A.C., Guilarte, T.R. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem 2000, 74(4): 1694-704.
83. Maeda, J., Higuchi, M., Inaji, M. et al. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res 2007, 1157: 100-11.
84. Oh, U., Fujita, M., Ikonomidou, V.N. et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol 2011, 6(3): 354-61.
85. Kreisl, W.C., Mbeo, G., Fujita, M., Zoghbi, S.S., Pike, V.W., Innis, R.B., McArthur, J.C. Stroke incidentally identified using improved positron emission tomography for microglial activation. Arch Neurol 2009, 66(10): 1288-9.
86. 11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 2010, 49(4): 2924-32.
87. 3H]PBR28 in human brain: Implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab 2010, 30(9): 1608-18.
88. Owen, D.R., Gunn, R.N., Rabiner, E.A. et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 2011, 52(1): 24-32.
89. Ma, J., Chen, T., Mandelin, J. et al. Regulation of macrophage activation. Cell Mol Life Sci 2003, 60(11): 2334-46.
90. Laskin, D.L., Sunil, V.R., Gardner, C.R., Laskin, J.D. Macrophages and tissue injury: Agents of defense or destruction? Annu Rev Pharmacol Toxicol 2011, 51: 267-88.
91. Ransohoff, R.M. Perry, V.H. Microglial physiology: Unique stimuli, specialized responses. Annu Rev Immunol 2009, 27: 119-45.
92. Montgomery, D L. Astrocytes: Form, functions, and roles in disease. Vet Pathol 1994, 31(2): 145-67.
93. Sofroniew, M.V.,Vinters, H.V. Astrocytes: Biology and pathology. Acta Neuropathol 2010, 119(1): 7-35.
94. Markiewicz, I., Lukomska, B. The role of astrocytes in the physiology and pathology of the central nervous system. Acta Neurobiol Exp (Wars) 2006, 66(4): 343-58.
95. Sofroniew, M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009, 32(12): 638-47.
96. Hamby, M.E., Sofroniew, M.V. Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics 2010, 7(4): 494-506.
97. 11C]MeSIMPY to b-amyloid plaques in patients with Alzheimer's disease. Curr Radiopharm 2009, 2(2): 129-36.
98. 11C]SB-13 PET. Am J Geriatr Psychiatry 2004, 12(6): 584-95.
99. 18F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 2003, 117(3): 723-30.
100. Klunk, W.E., Engler, H., Nordberg, A. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004, 55(3): 306-19.
101. Kudo, Y., Okamura, N., Furumoto, S. et al. 2-(2-[2-Dimethylaminothiazol- 5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007, 48(4): 553-61.
102. 18F]AV-45, a novel amyloid imaging agent - A pilot study. Nucl Med Biol 2010, 37(4): 497-508.
103. Nordberg, A., Rinne, J.O., Kadir, A., Langstrom, B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010, 6(2): 78-87.
104. Scheinin Noora, M., Scheinin, M., Rinne, J.O. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease. Q J Nucl Med Mol Imaging 2011, 55(3): 265-79.
105. Weiner, M.W., Aisen, P.S., Jack, C.R. Jr. et al. The Alzheimer's disease neuroimaging initiative: Progress report and future plans. Alzheimers Dement 2010, 6(3): 202-11.
106. 11C]PIB PET imaging. J Alzheimers Dis 2010, 21(3): 995-1003.
107. Pontecorvo, M.J., Mintun, M.A. PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimers Res Ther 2011, 3(2): 11.
108. Engler, H., Forsberg, A., Almkvist, O. et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129(Pt. 11): 2856-66.
109. 11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009, 73(15): 1186-92.
110. Koivunen, J., Scheinin, N., Virta, J.R. et al. Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study. Neurology 2011, 76(12): 1085-90.
111. 11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009, 36(10): 1629-38.
112. 11C]PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9(4): 363-72.
113. Bacskai, B.J., Frosch, M.P., Freeman, S.H. et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: A case report. Arch Neurol 2007, 64(3): 431-4.
114. Bacskai, B.J., Hickey, G.A., Skoch, J. et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 2003, 100(21): 12462-7.
115. Johnson, K.A., Gregas, M., Becker, J.A. et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007, 62(3): 229-34.
116. Dierksen, G.A., Skehan, M.E., Khan, M.A. et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 2010, 68(4): 545-8.
117. Greenberg, S.M., Grabowski, T., Gurol, M.E. et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol 2008, 64(5): 587-91.
118. Vinters, H.V., Gilbert, J.J. Cerebral amyloid angiopathy: Incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983, 14(6): 924-8.
119. Lockhart, A., Lamb, J.R., Osredkar, T. et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007, 130(Pt. 10): 2607-15.
120. Bolus, N.E., George, R., Washington, J., Newcomer, B.R. PET/MRI: The blended-modality choice of the future? J Nucl Med Technol 2009, 37(2): 63-71; quiz 2-3.
121. Judenhofer, M.S., Wehrl, H.F., Newport, D.F. et al. Simultaneous PET-MRI: A new approach for functional and morphological imaging. Nat Med 2008, 14(4): 459-65.
122. Pichler, B.J., Kolb, A., Nagele, T., Schlemmer, H. P. PET/MRI: Paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010, 51(3): 333-6.
123. 11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl Med Biol 2011, 38(2): 247-53.
124. Pike, V.W., Rash, K.S., Chen, Z. et al. Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. J Med Chem 2011, 54(8): 2687-700.
125. 18F]fluoro-N-[4-[6-(isopropylamino) pyrimidin-4-yl]- 1,3-thiazol-2-yl]-N- methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. Bioorg Med Chem Lett 2011, 21(10): 2998-3001.
126. 11C]MMTP: A potential PET ligand for mGluR1 receptors. Bioorg Med Chem Lett 2011, 20(12): 3499-501.
127. 18F]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse 2011, 65(2): 125-35.
128. 7 receptor PET radiotracers. Eur J Med Chem 2011, 46(8): 3455-61.
129. 11C]DR4446. J Labelled Compd Radiopharm 2002, 45: 857-66.
130. Stankoff, B., Wang, Y., Bottlaender, M. et al. Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A 2006, 103(24): 9304-9.
131. Wu, C., Wang, C., Popescu, D.C. et al. A novel PET marker for in vivo quantification of myelination. Bioorg Med Chem 2010, 18(24): 8592-9.
132. Wang, C., Wu, C., Zhu, J., Miller, R.H., Wang, Y. Design, synthesis, and evaluation of coumarin-based molecular probes for imaging of myelination. J Med Chem 2011, 54(7): 2331-40.
133. 18F]THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134(Pt. 4): 1089-100.